At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Custom panels can be now be validated and analyzed using ERASE-Seq variant caller
Alameda, CA, January 10, 2019 - Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced the launch of custom panel development services. Fluxion can validate an existing panel using ERASE-Seq, or can develop and supply custom kits based on the lab’s requirements.
Most current liquid biopsy technologies require chemical tags or “molecular barcodes” to verify that the starting DNA template molecule did not undergo an error during amplification or sequencing. These barcode approaches suffer from limited detection sensitivity, extensive validation of the chemistry, and technical challenges in developing larger panels.
Fluxion’s ERASE-Seq is panel and sequencer agnostic. ERASE-Seq can be easily adapted to any panel and sequencer through a straightforward statistical modeling process based on the user’s existing sequencing data. Once validation is completed, ERASE-Seq can be used via cloud-based or local software instances to analyze sequencing data. This allows labs with existing, validated panels for solid tissue to map the identical panel over to liquid biopsy use without any chemistry changes- no barcodes required! Typical sequencing depth is 20,000X per sample and achieves detection sensitivity of 0.1% MAF and below. Examples of panels that have been validated for ERASE-Seq include Swift 56G and Illumina Trusight Tumor 15.
Fluxion can also develop custom amplicon panels based on the user’s requirements, including panels up to 500 genes. Turnaround time for panel development is normally one week. Examples of recent projects include development of 50-gene melanoma panel for The Cleveland Clinic, and design of a custom panel for hepatocellular carcinoma.
Custom panel development is available immediately. Contact us for more information. ERASE-Seq is available via software license, or included for free with the purchase of a standard or custom panel.
About Fluxion Biosciences
Fluxion’s liquid biopsy solutions are revolutionizing how cancer is detected and treated. Fluxion’s pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion’s technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion Biosciences’ liquid biopsy capabilities, visit liquidbiopsy.fluxionbio.com.